An interventional study of ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast in Neuroendocrine Tumors, sponsored by University Hospitals Coventry and Warwickshire NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by University Hospitals Coventry and Warwickshire NHS Trust · Not applicable, Interventional, and Screening
Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that include: lack of a reference CgA standard; wide variations depending on the used assay in different laboratories; and varying sensitivity ranges from 60 to 90% with low specificity \<50%, depending on the population studied.
Surprisingly, and to the best of our knowledge, only three studies with small numbers of participants have been published that have investigated possible effects of food intake on the measurement of CgA. Most have been performed in healthy controls or patients on treatment with proton pump inhibitors for chronic gastritis (up to n = 11 per group) but only one study has investigated patients with GEP-NET, where n = 6 patients with gastric NET were included.
In this study, the investigators aim to assess the time dependent effects of normally ingested diet (5-item English breakfast; or tea or coffee; or ongoing fasted state) on plasma chromogranin A measurements, using timed measurements over 180 min following an > 10 hours overnight fast, in a randomised double-crossover design. The investigators aimed to include 25 - 35 patients with a histologically confirmed diagnosis of a GEP-NET of varying primary tumour location, tumour stage, grade; and presence or absence of treatment with long acting somatostatin analogues; as well as 10 - 15 healthy controls. In an additional small subgroup of patients who are initiated on treatment with GLP-1 analogues i.e. for type 2 diabetes or obesity, the investigators aim to establish whether injection of GLP-1 analogues has any effects on plasma CgA measurements.
GEP-NET patients:
CONTROLS:
Exclusion Criteria:
CONTROLS
ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
Other: ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
changes in plasma CgA measurements related to intake of food or caffeine containing beverages, as compared to ongoing fasted state
plasma CgA 0, 30, 60, 90, 120, 150 and 180 min
Time frame: up to 180 min
Plan to share: No
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospitals Coventry and Warwickshire NHS Trust